卵巢癌（OC）是一种常见的妇科恶性肿瘤，目前生存率仍然较低。TRPM2 在多种癌症中已被报道为生存预测因子，但在 OC 中尚未有相关研究。本研究的目的是探究 TRPM2 在 OC 中的作用和潜在机制。转录组数据和临床数据来自 TCGA、GTEx 和 GEO（GSE17260）。DriverDBv3 和 PrognoScan 用于分析生存相关性。通过 GSEA 分析揭示其潜在机制。使用 TIMER2.0 分析 TRPM2 与免疫评分、免疫细胞浸润之间的相关性。TRPM2 在 OC 中表达高，并且高 TRPM2 表达与不良预后相关，基于 Kaplan-Meier 曲线、单变量和多变量分析。富集分析显示 TRPM2 参与免疫相关通路。TRPM2 表达与免疫评分、B 细胞、T 细胞、巨噬细胞、嗜中性粒细胞和髓样树突状细胞等免疫细胞呈正相关。我们还发现 TRPM2 与包括 ICOSLG、CD40、CD86 等免疫检查点呈正相关。TRPM2 表达与 M2 型巨噬细胞呈正相关，但与 M1 型巨噬细胞呈无相关性。此外，TRPM2 与包括 NLRP3、NLRC4、NOD2、NOD1、IL1B、GSDMD 在内的凋亡相关基因呈强正相关。我们的研究证明 TRPM2 是卵巢癌的不良预后预测因子，并且与免疫微环境和凋亡相关。TRPM2 可能作为新的免疫治疗靶点，提高 OC 患者的生存率。© 2023. BioMed Central Ltd.，Springer Nature 的一部分。

Ovarian cancer (OC) is one of the most common gynecologic malignant cancers with the current survival rate remaining low. TRPM2 has been reported as a survival predictor in various cancers but not in OC. The aim of this study is to explore the role and its underlying mechanism of TRPM2 in OC.The transcriptome data and clinical data were obtained from TCGA, GTEx, and GEO (GSE17260). DriverDBv3 and PrognoScan were used to analyze survival correlations. GSEA analysis was performed to uncover the underlying mechanism. The correlations between TRPM2 and immune score, immune cell infiltration were analyzed by TIMER2.0.TRPM2 was highly expressed in OC and high TRPM2 expression was related to the poor prognosis based on the Kaplan-Meier curves, univariate and multivariate analysis. The enrichment analysis suggested that TRPM2 was involved in immune-related pathways. Positive correlations were also observed between TRPM2 expression and immune score and immune cells covering B cells, T cells, macrophage, neutrophil, and myeloid dendritic cells. We also found that TRPM2 was positively related to immune checkpoints including ICOSLG, CD40, CD86, etc. TRPM2 expression had a positive correlation with M2 macrophage, but not with M1 macrophage. Besides, TRPM2 showed a strong positive correlation with pyroptosis-related genes including NLRP3, NLRC4, NOD2, NOD1, IL1B, GSDMD.Our study demonstrated that TRPM2 is a poor prognostic prediction factor in ovarian cancer and is correlated to the immune microenvironment and pyroptosis. TRPM2 may act as a new immunotherapy target, which promoted the survival rate of OC patients.© 2023. BioMed Central Ltd., part of Springer Nature.